» Articles » PMID: 38877008

Association Between Antibody Responses Post-vaccination and Severe COVID-19 Outcomes in Scotland

Abstract

Several population-level studies have described individual clinical risk factors associated with suboptimal antibody responses following COVID-19 vaccination, but none have examined multimorbidity. Others have shown that suboptimal post-vaccination responses offer reduced protection to subsequent SARS-CoV-2 infection; however, the level of protection from COVID-19 hospitalisation/death remains unconfirmed. We use national Scottish datasets to investigate the association between multimorbidity and testing antibody-negative, examining the correlation between antibody levels and subsequent COVID-19 hospitalisation/death among double-vaccinated individuals. We found that individuals with multimorbidity ( ≥ five conditions) were more likely to test antibody-negative post-vaccination and 13.37 [6.05-29.53] times more likely to be hospitalised/die from COVID-19 than individuals without conditions. We also show a dose-dependent association between post-vaccination antibody levels and COVID-19 hospitalisation or death, with those with undetectable antibody levels at a significantly higher risk (HR 9.21 [95% CI 4.63-18.29]) of these serious outcomes compared to those with high antibody levels.

References
1.
Cheetham N, Kibble M, Wong A, Silverwood R, Knuppel A, Williams D . Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies. Elife. 2023; 12. PMC: 9940912. DOI: 10.7554/eLife.80428. View

2.
Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D . Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2021; 40(2):306-315. PMC: 8673730. DOI: 10.1016/j.vaccine.2021.12.006. View

3.
Shrotri M, Navaratnam A, Nguyen V, Byrne T, Geismar C, Fragaszy E . Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021; 398(10298):385-387. PMC: 8285117. DOI: 10.1016/S0140-6736(21)01642-1. View

4.
Nasr M, Geerling E, Pinto A . Impact of Obesity on Vaccination to SARS-CoV-2. Front Endocrinol (Lausanne). 2022; 13:898810. PMC: 9252434. DOI: 10.3389/fendo.2022.898810. View

5.
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View